Filing Details

Accession Number:
0001104659-10-055361
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-11-03 05:03:59
Reporting Period:
2010-08-13
Filing Date:
2010-11-03
Filing Date Changed:
2010-11-03
Accepted Time:
2010-11-03 06:03:59
Original Submission Date:
Issuer
Cik Name Symbol Sector (SIC) IRS No
744962 Nutrition 21 Inc NXXI Biological Products, (No Disgnostic Substances) (2836) 112653613
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1498510 A David Holmes 265 Harrison Avenue
Kearny NJ 07032
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings
Common Stock Acquisiton 2010-11-02 3,725,719 $0.02 18,725,719
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Pharmachem Laboratories, Inc.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Convertible Preferred Shares Series J 8% Acquisiton 2010-11-02 3,000 $281.37 2,467,511 $1.22
Common Stock Warrants Acquisiton 2010-11-02 1,134,966 $0.00 1,134,966 $1.22
Common Stock Warrants Acquisiton 2010-11-02 777,778 $0.00 777,778 $2.20
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
21,193,230 No 4 P Indirect
22,328,196 2008-03-11 2013-03-11 No 4 P Indirect
23,105,974 2008-03-11 2013-03-11 No 4 P Indirect
Footnotes
  1. The securities reported herein (the "Securities") are owned by Pharmachem Laboratories, Inc.
  2. The Securities may be deemed to be indirectly beneficially owned by David A. Holmes under Rule 16a-1(a)(2)(iii), since David Holmes is the controlling shareholder of Pharmachem Laboratories, Inc.
  3. Anytime after September 10, 2007.
  4. According to the Certificate of Amendment of the Certificate of Designation of the Company which creates the Series J 8% Convertible Preferred Stock and was filed with the Securities Exchange Commission on September 12, 2007, the preferred shares are convertible at any time at the option of the holder. Additionally, on the fourth anniversary of the issue date, the Company shall redeem the then outstanding Preferred Stock.
  5. This Number Includes (i) 15,000,000 Shares of Common Stock held directly by the Reporting Person; (ii) 3,725, 719 shares of Common Stock acquired By Pharmachem Laboratories, Inc. and indirectly beneficially owned by the reporting person, and (iii) 2,467,511 shares of Common Stock which may be issued by Nutrition 21, Inc. upon conversion of 3,000 shares of Series J8% Convertible Preferred and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Securities and Exchange Act of 1934, as amended.
  6. This Number Includes (i) 15,000,000 Shares of Common Stock held directly by the Reporting Person; (ii) 3,725, 719 shares of Common Stock acquired By Pharmachem Laboratories, Inc. and indirectly beneficially owned by the reporting person, (iii) 2,467,511 shares of Common Stock which may be issuable by Nutrition 21, Inc. upon conversion of 3,000 shares of Series J8% Convertible Preferred and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Securities and Exchange Act of 1934, as amended (the "Act"), and (iv) 1,134,966 shares of Common Stock issuable by Nutrition 21, Inc. upon exercise of the warrants and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Act.
  7. This Number Includes (i) 15,000,000 Shares of Common Stock held directly by the Reporting Person; (ii) 3,725, 719 shares of Common Stock acquired By Pharmachem Laboratories, Inc. and indirectly beneficially owned by the reporting person, (iii) 2,467,511 shares of Common Stock which may be issuable by Nutrition 21, Inc. upon conversion of 3,000 shares of Series J8% Convertible Preferred and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Securities and Exchange Act of 1934, as amended (the "Act"), (iv) 1,134,966 shares of Common Stock issuable by Nutrition 21, Inc. upon exercise of the warrants and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Act, and (v) 777,778 shares of Common Stock issuable by Nutrition 21, Inc. upon exercise of the warrants and deemed beneficially owned by the Reporting Person pursuant to Rule 13d-3(d)(1)(i) of the Act.
  8. No price was given to the warrants as they were attached to the Convertible Preferred Shares Series J 8%.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!